While it is notable that adjudicated major adverse cardiovascular event rates were lower in the bempedoic acid treatment arms in both trials, these were trends that did not reach statistical significance.
← all excerpts
Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease.
1
—
—